YD Bio Limited has entered into a binding letter of intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. (SSMC), a Taiwan-based dendritic cell immunotherapy platform. The agreement involves a combination of newly issued YD Bio Ltd shares and cash, with SSMC's founder and major shareholders set to receive shares through a swap, while other shareholders can choose between cash or shares. Newly issued shares will be subject to lock-up periods of six months for general shareholders and one year for specific shareholders. The transaction aims to accelerate YD Bio Ltd’s expansion into advanced cell and gene therapies, complementing its recent integration of DNA-methylation-driven AI platforms for cancer diagnostics. The acquisition is expected to enhance research and development capabilities and broaden the company’s portfolio in innovative cancer treatment solutions. Completion is subject to due diligence and other customary conditions, with closing targeted shortly after March 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645154-en) on January 29, 2026, and is solely responsible for the information contained therein.